Cell Envision Ltd. completed an angel round that will help expand its presence in the U.S. and Europe. Taiwan-based Cell Envision has developed a self-assembled cell arrangement (SACA) monitoring system that can improve patient survival rates of cancer, together with enhancements in reproductive medicine.
Having initiated its first two clinical trials in non-small-cell lung cancer since January, Nuvalent Inc. said it expects to unveil preliminary dose-escalation data before year-end. Ahead of the data, Nuvalent's phase I/II Arros-1 trial evaluating NVL-520, a kinase inhibitor, in patients with advanced ROS1-positive NSCLC and other solid tumors, continues to enroll participants.
How to get reasonable efficacy in cancer without toxicity – problematic especially in older patients – is a dilemma made ever more poignant by the advent of CAR T therapies and bispecific antibodies, which have been showing overall response rates of about 70%, but with side effects that can severely limit their use. Invariant natural killer T cells may provide an answer, and New York-based Mink Therapeutics Inc. aims to find out.
Japan’s Healios K.K. is in discussions with Japan’s Pharmaceutical and Medical Devices Agenc about the regulatory path forward for its Multistem somatic stem cell products, for which it conducted phase II/III trials in ischemic stroke and a phase II trial in acute respiratory distress syndrome.
Regulatory T cells (Tregs) are contributors of tumor immune evasion; Ikaros family zinc finger protein 2 (IKZF2) plays a crucial role in the maintenance of function and stability of Tregs. IKZF2-deificent tumoral Tregs produce inflammatory cytokines and enhance antitumoral immunity in mice.
Txinno Bioscience has presented benzotriazole derivatives acting as ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (E-NPP 1) inhibitors reported to be useful for the treatment of cancer.
The Broad Institute, Janssen Biotech and Massachusetts General Hospital have divulged new serine/threonine-protein kinase SIK2 (QIK) inhibitors reported to be useful for the treatment of cancer and autoimmune disease.
3T Biosciences Inc. raised $40 million in a series A funding round to take forward a platform for identifying novel T-cell receptors (TCR) and their targets, which is based on the work of scientific co-founder K. Christopher Garcia of Stanford University.
Shandong University scientists have evaluated structural modification of parbendazole to derive potential treatments for head and neck squamous cell carcinoma (HNSCC).
RSS
